Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer

This article originally appeared here.
Share this content:
Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer
Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer

MONDAY, May 8, 2017 (HealthDay News) -- For postmenopausal breast cancer patients receiving aromatase inhibitors, oral osteoporosis therapy (OPT) is associated with improved survival, according to a study published online May 2 in Cancer.

Allan Lipton, M.D., from the Penn State Hershey Medical Center, and colleagues enrolled 7,576 postmenopausal women in the MA.27 phase 3 adjuvant trial. Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis and were followed for event-free and distant disease-free survival (EFS and DDFS).

The researchers found that osteoporosis was reported by 654 women (8.6 percent) at baseline and by 1,294 women in total. At baseline, oral OPT was received by 10.8 percent of the women and by 36 percent in total. There were 693 EFS events (9.15 percent) and 321 DDFS events (4.2 percent) during a median follow-up of 4.1 years. There was no correlation noted for EFS or DDFS with osteoporosis. There were few EFS events before OPT initiation, with no substantial evidence of a time-differing effect on outcomes. OPT correlated with improved EFS and DDFS (hazard ratios for yes versus no, 0.67 and 0.57, respectively). There was no association for time-differing OPT with EFS. There was no correlation for OPT with incidence of visceral-only metastasis.

"Oral OPT, administered to postmenopausal breast cancer patients receiving adjuvant aromatase inhibitor therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time-dependent effect) did not affect the outcome," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »